Gene
TOP2A
DNA topoisomerase II alpha
Explore in graph →CI-GENE-00035889HGNC:11989 ENSG00000131747 NCBI 7153 CIViC Cancer geneApproved
Curated evidence
Clinical evidence (3)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 15486187
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TOP2A EXPRESSION1 | ||||||||
| Doxorubicin | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID909In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin… (full text at CIViC) PMID 15486187 · Durbecq et al., 2004 · Open in CIViC | civic |
| TOP2A TOP2A/902 | ||||||||
| Etoposide | Leukemia | Predictive | D | Supports Resistance | 4 | submitted | EID9634In an in vitro study, leukemia cells expressing TOP2A/90 show increased inhibition (p < 0.025) upon KD of TOP2A/90 when treated with etoposide. Moreover cells expressing TOP2A/170 but not TOP2A/90 sho… (full text at CIViC) PMID 29514855 · | |
Cohorts
Alteration frequency by cohort (8)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
- Source
- cBioPortal for Cancer Genomics (public studies)
- Dataset
- cBioPortal mutated genes by study
- Version
- cbioportal-2026-09-01
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- cohort
- License
- ODC Open Database License (ODC-ODbL) unless otherwise noted per study; attribution to the original studies required
- Run
- ING-CBIOPORTAL-20260908-000001
| Cohort | Mapped cancer | Alteration | Affected (n) | Profiled (n) | Frequency (%) | Rank in cohort | Source |
|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma (TCGA GDC, 2025) chol_tcga_gdc | Cholangiocarcinoma | Ssm | 3 | 51 | 5.9% | 50 |
Literature
Linked publications (1)
25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
· Mol Cancer Ther · 2004 · PMID 15486187 · validated civic_curation pubmed